PDF
ePub
Citation
Print
Abstract
Purpose
To perform an economic evaluation of the different treatment methods available for primary open-angle glaucoma in a Korean set-ting, including medication, selective laser trabeculoplasty, or surgery.
Methods
Three independent Markov chains were constructed for each treatment option to simulate treatment progress and to evaluate the total treatment costs for each initial strategy. The Markov chain consisted of different stages (5, 10, 20 stages), with each stage being one year. Assuming 1000 patients, a Monte Carlo simulation was iterated 1000 times to evaluate the cost of treatment over 5, 10 and 20 years.
Results
During the initial five years, medication as the initial treatment was the most expensive, whereas laser trabeculoplasty was the cheapest. After ten years, surgery became the cheapest treatment. In ten years, if the success rate of surgery is greater than 30.1%, it was more economic to choose surgery as the initial treatment. For laser trabeculoplasty, if the success rate was greater than 16.3%, laser treatment was more economical than was medication. Our model shows that only if the annual cost of medication decreases to 60,000 won or 55,000 won, then the cost of choosing medication as the initial treatment strategy will be more economical than that of laser therapy or surgery, respectively.
References
1. Friedman DS, Wilson MR, Liebmann JM, et al. An evidencebased assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004; 138:S19–31.
2. Cantor LB, Katz LJ, Cheng JW, et al. Economic evaluation of medication, laser trabeculoplasty and filtering surgeries in treating patients with glaucoma in the US. Curr Med Res Opin. 2008; 24:2905–18.
3. Payet S, Denis P, Berdeaux G, et al. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France. Clin Drug Investig. 2008; 28:183–98.
4. Zaninetti M, Ravinet E. Two-year outcomes of selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension. J Fr Ophthalmol. 2008; 31:981–6.
5. Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye. 2009; 23:132–40.
6. Lee KW, Park CK, Moon JI. Cost-effectiveness of early surgical or medical therapy for primary open angle glaucoma: a decision ana-lytic model. J Korean Ophthalmol Soc. 2003; 44:1543–50.
7. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998; 7:95–104.
8. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of re-source utilisation in Europe. Br J Ophthalmol. 2005; 89:1245–9.
9. Moon SC, Rho SH, Ahn HB. The clinical effect of trabeculectomy. J Korean Ophthalmol Soc. 1997; 38:839–48.
10. Nouri-Mahdavi K, Brigatti L, Weitzman M, Caprioli J. Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology. 1995; 102:1760–9.
11. Feiner L, Piltz-Seymour JR. Collaborative Initial Glaucoma Treatment Study. Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol. 2003; 14:106–11.
12. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994; 101:1651–6.
13. Shirato S, Kitazawa Y, Mishima S. A critical analysis of the trabeculectomy results by a prospective follow-up design. Jpn J Ophthalmol. 1982; 26:468–80.
14. Park MH, Moon JI. Selective laser trabeculoplasty in fertile women with open angle glaucoma or ocular hypertension. J Korean Ophthalmol Soc. 2007; 48:1494–9.
15. Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998; 105:2082–8.
16. Kano K, Kuwayama Y, Mizoue S, Ito N. Clinical results of selective laser trabeculoplasty. Nippon Ganka Gakkai Zasshi. 1999; 103:612–13.
17. Gracner T, Pahor D, Gracner B. Efficacy of selective laser trabeculoplasty in the treatment of primary open-angle glaucoma. Klin Monbl Augenheilkd. 2003; 220:848–52.
18. McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma. 2006; 15:124–30.
19. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol. 2003; 121:957–60.
20. Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology. 2004; 111:1853–9.
21. Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol. 2004; 32:368–72.
22. Buys YM. Economics of selective laser trabeculoplasty as primary therapy for glaucoma. Can J Ophthalmol. 2006; 41:419–20.
23. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial. Br J Ophthalmol. 2006; 90:1490–4.
24. Knox FA, Barry M, McGowan B, O’Brien C. The rising cost of glaucoma drugs in Ireland 1996-2003. Br J Ophthalmol. 2006; 90:162–5.
25. Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care. 2009; 15:226–32.
26. Wu JM, Siddiqui NY, Amundsen CL, et al. Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009; 181:2181–6.
27. Rowe AJ, Meneghetti AT, Schumacher PA, et al. Perioperative analysis of laparoscopic versus open liver resection. Surg Endosc. 2009; 23:1198–203.
28. Tilney HS, Lovegrove RE, Purkayastha S, et al. Comparison of colonic stenting and open surgery for malignant large bowel obstruction. Surg Endosc. 2007; 21:225–33.
29. Goodnough LT, Despotis GJ, Merkel K, Monk TG. A randomized trial comparing acute normovolemic hemodilution and pre-operative autologous blood donation in total hip arthroplasty. Transfusion. 2000; 40:1054–7.
Figures 1.
Increase in costs of national health insurance. Note that there is a steady increase in both the total cost and disease (glaucoma)-specific cost from 2004 to 2007.
Figure 2.
The Markov model used in this study. Three independent Markov chain models were constructed for each treatment option (medication, surgery, laser) to simulate the transition of treatment progress and to evaluate the total treatment costs associated with each strategy.
Figure 3.
Markov probability analysis for the group primarily treated with medication (A), primarily treated with laser (B) and primarily treated with surgery (C). One stage is regarded as 1 year. Note that in panel (B), poten-tially well lasered status only appear once after initiation of the treatment as laser treatment is only performed once. The people who are eventually successfully treated with laser therapy are incorporated into successful treatment after stage 1.
Figure 4.
Monte Carlo for the group primarily treated with medication (A), primarily treated with laser (B) and primarily treated with surgery (C). The 10-year cumulative costs were 1,188,383 won, 835,811 won and 758,100 won for patients selecting medication, laser trabeculoplasty and operation as the initial treatment strategy, respectively.
Table 1.
List of the eye drops with respective cost (2009 July current cost)
Table 2.
The cost for surgery and selective laser trabeculoplasty (2009 July current cost)
Table 3.
The total cost for each treatment methods during different time scales (5, 10, 20 years) (2009 July current cost)
| 5 years | 10 years | 20 years | |
|---|---|---|---|
| Medication | 689,921 | 1,188,383 | 1,706,869 |
| Laser | 656,194 | 835,811 | 901,366 |
| Surgery | 757,400 | 758,100 | 758,800 |
Table 4.
The total cost for surgery and selective laser trabeculoplasty depending on the success rate of each treatment after 10 years (2009 July current cost)
Table 5.
The total cost for medication depending on the annual cost of medication. Only if the annual cost of medication decreases to 55,000 won, then the cost of choosing medication of the initial treatment strategy will be eco-nomical than choosing laser or operation
Table 6.
The cost of each treatment options depending on the cost of laser treatment. This analysis was performed to simulate the clinical situation where selective laser trabeculoplasty is first applied over 180 degrees followed by additional trabeculoplasty over remained 180 degrees. Note the increase of the cost for laser treatment in the latter case.
XML Download